AstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its ...

The FDA has approved a new drug called ensartinib for adults with a type of lung cancer called ALK-positive non-small-cell lung cancer (NSCLC).

Feedback from the EU indicated that the trial results, which the application was based on, showed that the drug did not ...

It is further described as a targeted therapy "designed to improve outcomes in patients who have tried all other treatment ...

When supplies of certain generic, platinum-based cancer chemotherapies dwindled in 2023, oncologists feared it might ...

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

Lung cancer is one of the most common and deadly cancers that occurs due to poor lung health. However, early symptoms can lead to treatment that makes a big difference. Discover the various symptoms ...

Sep. 25, 2024 — Researchers have tested a combination of treatments in mice with lung cancer and shown that these allow immunotherapies to target non-responsive ... Experimental mRNA Cancer ...

AstraZeneca PLC has withdrawn its Dato-DXd NSQ NSCLC application from the European Union. The decision marks a significant shift in the company's approach to non-small cell lung cancer treatment ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...